Krystal Biotech develops redosable gene therapies delivered with its proprietary HSV-1 viral vector platform, focused on rare and serious diseases. Its lead product VYJUVEK is a topical gene therapy for dystrophic epidermolysis bullosa, a genetic blistering skin disorder. The company aims to expand the same platform into additional dermatologic and other genetic conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 96 | — | 38.3 | 44.3% |
| Q3 2025 | 97.8 | — | 79.4 | 114.1% |
| Q4 2025 | 107.1 | — | 51.4 | 16.8% |
| Q1 2026 | 116.4 | — | 55.9 | 58% |
| Q2 2026 | 119.2 | 24.1% | 54.8 | 42.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: FirstCash Holdings, Inc. (FCFS), Zions Bancorporation, National Association (ZION), 10x Genomics, Inc. (TXG), Sirius XM Holdings Inc. (SIRI), Cognex Corporation (CGNX), Liberty Live Holdings, Inc. (LLYVK)